Chemical Tools

NEXUS provides access to unique custom designed small-molecule libraries with up to 24’000 compounds for cell-based or biochemical screening. All available libraries are designed complementary to each other thus allowing medium to high-throughput screens with single or multiple libraries.
We offer a drug-like and a lead-like diversity set (16’000 and 24’000 compounds), two advanced chemistry sets (1’250 and 1’500 compounds) as well as two clinical compound sets (466 and 2’425 compounds). A Kinase Modulator and a Natural Derivatives Libraries complement our small molecule portfolio*.
* Our small-molecule libraries are only available for screening campaigns performed at NEXUS.
- 16'046 compounds
- 10 mM solution in DMSO Stock
The NEXUS Diversity Set consists of two complementary subsets:
- Pharmacophore Diversity Subset (8'775 compounds)
- Structural Diversity Subset (7'273 compounds).
The Pharmacophore Diversity Subset covers the whole pharmacophore drug-like chemical space, whereas the NEXUS Structural Diversity Subset represents maximum chemical structural diversity of commercially available compounds.

- external page 2'425 unique compounds
- 10 mM solution in DMSO Stock
This library has been selected from various suppliers and comprises most of drugs either approved by FDA or with INN, BAN and/or JAN status that are commercially available for experimental purposes.

- external page 1300 compounds
This library has been selected from Selleck Chemicals supplier and comprises drugs approved by FDA.
- external page 466 compounds
- 10 mM solution in DMSO Stock
A unique collection of clinical compounds in phases 1-3 related to oncology, cardiology, anti-inflammatory, immunology, neuropsychiatry, analgesia.

Registered users can download the compound lists and structure information of the individual libraries directly from our web-page. Please contact us to register by e-mail using your institutional e-mail address.
Important: Requests from private e-mail addresses (such as Gmail, Hotmail, etc.) as well as due to technical restraints, direct requests via our sharepoint instance cannot be considered.